Evidence map›Paper›PMID 40120052›Full record

ReviewAging clinical and experimental research2025

Health outcomes of sarcopenia: a consensus report by the outcome working group of the Global Leadership Initiative in Sarcopenia (GLIS).

Charlotte Beaudart, Julian Alcazar, Ivan Aprahamian, John A Batsis, Yosuke Yamada, Carla M Prado, Jean-Yves Reginster, Dolores Sanchez-Rodriguez, Wee Shiong Lim, Marc Sim and 4 more

Registry-linked trialAbstract readReviewConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Review in Aging clinical and experimental research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07689994 (Evaluation of the Effect of a Seaweed Flour- and Leucine-Enriched Food on Metabolic and Inflammatory Status in Older Adults With Probable Sarcopenia or Sarcopenia), which is not on this map. Cited by 85 papers, 14 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
85citing papers in PubMed, 14 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07689994 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

Evaluation of the Effect of a Seaweed Flour- and Leucine-Enriched Food on Metabolic and Inflammatory Status in Older Adults With Probable Sarcopenia or Sarcopenia: A Prospective, Controlled, Randomized, Double-Blind, Three-Arm Parallel Clinical Trial

TypeinterventionalSponsorFinis Terrae UniversityRan2026 to 2027Enrolled102ConditionsSarcopenia in ElderlyArmsStandard chocolate-flavored cake, Leucine-Enriched Chocolate Cake, Leucine Plus Seaweed Flour-Enriched Chocolate Cake
3 · Its place in the literature

Who cites it

85 citing papers in PubMed, 14 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Circulating biomarkers in older adults with and without sarcopenia: a systematic review and meta-analysis.The journals of gerontology. Series A, Biological sciences and medical sciences · 2026
    Pooled it
  5. Pooled it
  6. Pooled it
  7. How Pragmatic Are Sarcopenia Intervention Studies? A Systematic Review.Journal of cachexia, sarcopenia and muscle · 2026
    Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

25 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Charlotte BeaudartPublic Health Aging Research & Epidemiology (PHARE) Group, Research Unit in Clinical, Pharmacology and Toxicology (URPC), Faculty of Medicine, NAmur Research Institute for LIfe Sciences (NARILIS), University of Namur, Namur, Belgium. charlotte.beaudart@unamur.be.ORCID http://orcid.org/0000-0002-0827-5303
Julian AlcazarGENUD Toledo Research Group, Faculty of Sport Sciences, University of Castilla-La Mancha, Toledo, Spain.
Ivan AprahamianDivision of Geriatrics, Department of Internal Medicine, Jundiaí Medical School, Jundiaí, Brazil.
John A BatsisDivision of Geriatric Medicine, School of Medicine, and the Department of Nutrition, Gillings School of Global Public Health, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, 27599, USA.
Yosuke YamadaDepartment of Medicine and Science in Sports and Exercise, Graduate School of Medicine, Tohoku University, Sendai, Miyagi, 980-8575, Japan.
Carla M PradoDepartment of Agricultural, Food and Nutritional Science, University of Alberta, Edmonton, AB, Canada.
Jean-Yves ReginsterChair for Biomarkers of Chronic Diseases, College of Science, King Saud University, Riyadh, Kingdom of Saudi Arabia.
Dolores Sanchez-RodriguezRehabilitation Research Group, Hospital del Mar Medical Research Institute, 08003, Barcelona, Spain.
Wee Shiong LimInstitute of Geriatrics and Active Ageing, Tan Tock Seng Hospital, Singapore, Singapore.
Marc SimSchool of Medical and Health Sciences, Nutrition and Health Innovation Research Institute, Edith Cowan University, Joondalup, WA, Australia.
Stephan von HaehlingDepartment of Cardiology and Pneumology, University of Göttingen Medical Center, Göttingen, Germany.
Jean Woo *Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.
Gustavo Duque *Muscle & Geroscience Group, Research Institute of the McGill University Health Centre, BoneMontreal, QC, Canada.
Global Leadership Initiative in Sarcopenia (GLIS) group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Global Leadership Initiative in Sarcopenia (GLIS) aims to standardize the definition and diagnostic criteria for sarcopenia into one unifying, common classification. Among other actions to achieve this objective, the GLIS has organized three different working groups (WGs), with the WG on outcomes of sarcopenia focusing on reporting its health outcomes to be measured in clinical practice once a diagnosis has been established. This includes sarcopenia definitions that better predict health outcomes, the preferred tools for measuring these outcomes, and the cutoffs defining normal and abnormal values. The present article synthesizes discussions and conclusions from this WG, composed of 13 key opinion leaders from different continents worldwide. Results rely on systematic reviews, meta-analyses, and relevant cohort studies in the field. With a high level of evidence, sarcopenia is significantly associated with a reduced quality of life, a higher risk of falls and fractures and a higher risk of mortality. Sarcopenia has been moderately associated with a higher risk of reduced instrumental activities of daily living (IADL). However, the GLIS WG found only inconclusive level of evidence to support associations between sarcopenia and higher risks of hospitalization, nursing home admission, mobility impairments, and reduced basic activities of daily living (ADL). This limitation underscores the scarcity of longitudinal studies, highlighting a barrier to understanding its progression and implications over time.

Indexed as

SarcopeniaAccidental FallsActivities of Daily LivingAgedHumansLeadershipQuality of LifeADLFallsFracturesGLISHospitalizationIADLMobilityMortalityMuscle massMuscle strengthNursing home admissionOutcomesPhysical performanceQuality of lifeSarcopenia

Identifiers

PMID40120052
PMCPMC11929733

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.